TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.
TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.
Peter L. Hoang pens a personal letter to TapImmune’s shareholders.
TapImmune will be attending and presenting at the 20th Bioflorida Conference in St. Petersburg, Florida.
TapImmune Welcomes Peter L. Hoang as President and Chief Executive Officer.
TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, August 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the second quarter 2017.
TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments
TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.
TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology
Hear from Randal H. Henderson, MD,Professor,Department of Radiation Oncology and Associate Medical Director at the UF Health Proton Therapy Institute, and enjoy a panel discussion led by Glynn Wilson, PhD, Chairman & CEO of TapImmune, Inc.
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer
TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).
TapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors
TapImmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately $6.82 million in a private placement transaction with accredited investors and from the exercise of certain outstanding Series E warrants by certain existing institutional investors.